Modified solid in oil nanodispersion containing vemurafenib-lipid complex- in vitro/ in vivo study

Background: Vemurafenib (VEM) was a licensed drug for the treatment of skin melanoma and is available only in the market as oral tablets prescribed in huge doses (1920 mg/day). One reason for the high dose is vemurafenib's low oral bioavailability. Methods: VEM-lipid complex (DLC) was predicted...

Descripción completa

Detalles Bibliográficos
Autores principales: Almajidi, Yasir Q., Maraie, Nidhal K., Raauf, Ayad M. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627402/
https://www.ncbi.nlm.nih.gov/pubmed/36339973
http://dx.doi.org/10.12688/f1000research.123041.2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627402/
https://www.ncbi.nlm.nih.gov/pubmed/36339973
http://dx.doi.org/10.12688/f1000research.123041.2

Ejemplares similares